Q2-osavuosiraportti
Vain PDF
87 päivää sitten
0,8572 SEK/osake
Viimeisin osinko
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
180
Myynti
Määrä
2 110
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 89 | AVA | NON | ||
| 324 | AVA | NON | ||
| 1 060 | AVA | NON | ||
| 962 | NON | NON | ||
| 2 000 | ENS | NON |
Ylin
6,44VWAP
Alin
6,02VaihtoMäärä
0,4 69 421
VWAP
Ylin
6,44Alin
6,02VaihtoMäärä
0,4 69 421
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 20.11. 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Yhtiökokous | 22.5. | |
| 2024 Q4-osavuosiraportti | 27.2. | |
| 2024 Q3-osavuosiraportti | 19.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
13.10.13.10.Tämä julkaisu on poistettu.
·1 päivä sitten · MuokattuThe market clearly wants to see visible proof that the product can be sold before it reacts to Coegin's first product launch. Gents is uncertain about the product, as they are not buying a portion for stock, but only buying in after pre-orders. Strange, when they now describe and refer to the product so positively.
·27.8.Does anyone know what the uptick this week is due to? Can't find any news?
·17.9.When a stock goes down, someone is interested in buying it because no one wants to pay too much and there is no news in this stock.- ·12.8.Yeah, right BV of 77 million Does anyone seriously think that foreign interests are looking at the company? Possibly someone on the board has woken up and thought that since they have a website, they are global because the whole world can read about them. Seriously, I think that the few kronor they have in the coffers should be used for something more sensible than paying for correct translations, otherwise it's because they will soon be begging for new money and therefore diffuse pms should be sent out so no one understands.
9.7.9.7.@Shareville: Written in the English language you see below yet another message sent to CEO today. The idea is to place as much pressure as possibly possible on Jens Eriksson prior to next quarterly announcement as of 21th August. Do fell free to join in and contact Jens Eriksson - the more who raise their voices, the bigger the chance is he will disclose substantiated information to the market. He should know for sure his story-telling days are over........ <xxxx@xxxx.dk> 09/07/202510:47 To: xxxx@xxxx.dk, je@coeginpharma.com Cc: info@coeginpharma.com, erlend@sarsia.com Dear Jens, First, credit is due to you for now using the appropriate channels of the Swedish stock exchange to inform the market of developments at Coegin Pharma AB. Transparency is a vital step forward, and I thank you for taking that responsibility seriously. That said, the market's perception of Coegin Pharma AB remains negative. Despite recent announcements—such as the 80% reduction in production costs for the hair growth product and the presentation of its packaging prototype—the market has not responded positively. The share price continues its downward trend, signaling a lack of confidence that these updates signify meaningful progress toward commercialization and, ultimately, positive cash flow. Why is this the case? The answer appears to be straightforward: the market has grown weary of what it perceives as prolonged storytelling rather than evidence-backed execution. Cost savings and packaging design are not, in themselves, proof of market readiness or commercial viability. They do not address the key concerns investors have about Coegin Pharma AB's ability to evolve into a profitable startup. As CEO, it is now essential to provide the market with concrete, evidence-based information that substantiates the company’s go-to-market capability. Specifically, stakeholders need to see: - Names of signed partners and distributors - The geographic reach and coverage of these distribution networks - A clear, detailed product launch timeline including specific milestones - Transparent communication regarding the company’s financial position and upcoming funding requirements These are basic and expected elements of investor communication at this stage of company development. With this in mind, I strongly encourage you to sharpen the focus and clarity of Coegin Pharma AB’s messaging ahead of the upcoming quarterly report, scheduled for publication on August 21st. This is an opportunity to shift the narrative through concrete disclosures that build trust and demonstrate that the company is entering a phase of measurable execution. Sincerely, Xxxx Xxxx
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
87 päivää sitten
0,8572 SEK/osake
Viimeisin osinko
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 13.10.13.10.Tämä julkaisu on poistettu.·1 päivä sitten · MuokattuThe market clearly wants to see visible proof that the product can be sold before it reacts to Coegin's first product launch. Gents is uncertain about the product, as they are not buying a portion for stock, but only buying in after pre-orders. Strange, when they now describe and refer to the product so positively.
- ·27.8.Does anyone know what the uptick this week is due to? Can't find any news?·17.9.When a stock goes down, someone is interested in buying it because no one wants to pay too much and there is no news in this stock.
- ·12.8.Yeah, right BV of 77 million Does anyone seriously think that foreign interests are looking at the company? Possibly someone on the board has woken up and thought that since they have a website, they are global because the whole world can read about them. Seriously, I think that the few kronor they have in the coffers should be used for something more sensible than paying for correct translations, otherwise it's because they will soon be begging for new money and therefore diffuse pms should be sent out so no one understands.
- 9.7.9.7.@Shareville: Written in the English language you see below yet another message sent to CEO today. The idea is to place as much pressure as possibly possible on Jens Eriksson prior to next quarterly announcement as of 21th August. Do fell free to join in and contact Jens Eriksson - the more who raise their voices, the bigger the chance is he will disclose substantiated information to the market. He should know for sure his story-telling days are over........ <xxxx@xxxx.dk> 09/07/202510:47 To: xxxx@xxxx.dk, je@coeginpharma.com Cc: info@coeginpharma.com, erlend@sarsia.com Dear Jens, First, credit is due to you for now using the appropriate channels of the Swedish stock exchange to inform the market of developments at Coegin Pharma AB. Transparency is a vital step forward, and I thank you for taking that responsibility seriously. That said, the market's perception of Coegin Pharma AB remains negative. Despite recent announcements—such as the 80% reduction in production costs for the hair growth product and the presentation of its packaging prototype—the market has not responded positively. The share price continues its downward trend, signaling a lack of confidence that these updates signify meaningful progress toward commercialization and, ultimately, positive cash flow. Why is this the case? The answer appears to be straightforward: the market has grown weary of what it perceives as prolonged storytelling rather than evidence-backed execution. Cost savings and packaging design are not, in themselves, proof of market readiness or commercial viability. They do not address the key concerns investors have about Coegin Pharma AB's ability to evolve into a profitable startup. As CEO, it is now essential to provide the market with concrete, evidence-based information that substantiates the company’s go-to-market capability. Specifically, stakeholders need to see: - Names of signed partners and distributors - The geographic reach and coverage of these distribution networks - A clear, detailed product launch timeline including specific milestones - Transparent communication regarding the company’s financial position and upcoming funding requirements These are basic and expected elements of investor communication at this stage of company development. With this in mind, I strongly encourage you to sharpen the focus and clarity of Coegin Pharma AB’s messaging ahead of the upcoming quarterly report, scheduled for publication on August 21st. This is an opportunity to shift the narrative through concrete disclosures that build trust and demonstrate that the company is entering a phase of measurable execution. Sincerely, Xxxx Xxxx
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
180
Myynti
Määrä
2 110
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 89 | AVA | NON | ||
| 324 | AVA | NON | ||
| 1 060 | AVA | NON | ||
| 962 | NON | NON | ||
| 2 000 | ENS | NON |
Ylin
6,44VWAP
Alin
6,02VaihtoMäärä
0,4 69 421
VWAP
Ylin
6,44Alin
6,02VaihtoMäärä
0,4 69 421
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 20.11. 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Yhtiökokous | 22.5. | |
| 2024 Q4-osavuosiraportti | 27.2. | |
| 2024 Q3-osavuosiraportti | 19.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
87 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 20.11. 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Yhtiökokous | 22.5. | |
| 2024 Q4-osavuosiraportti | 27.2. | |
| 2024 Q3-osavuosiraportti | 19.11.2024 |
Datan lähde: Millistream, Quartr
0,8572 SEK/osake
Viimeisin osinko
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 13.10.13.10.Tämä julkaisu on poistettu.·1 päivä sitten · MuokattuThe market clearly wants to see visible proof that the product can be sold before it reacts to Coegin's first product launch. Gents is uncertain about the product, as they are not buying a portion for stock, but only buying in after pre-orders. Strange, when they now describe and refer to the product so positively.
- ·27.8.Does anyone know what the uptick this week is due to? Can't find any news?·17.9.When a stock goes down, someone is interested in buying it because no one wants to pay too much and there is no news in this stock.
- ·12.8.Yeah, right BV of 77 million Does anyone seriously think that foreign interests are looking at the company? Possibly someone on the board has woken up and thought that since they have a website, they are global because the whole world can read about them. Seriously, I think that the few kronor they have in the coffers should be used for something more sensible than paying for correct translations, otherwise it's because they will soon be begging for new money and therefore diffuse pms should be sent out so no one understands.
- 9.7.9.7.@Shareville: Written in the English language you see below yet another message sent to CEO today. The idea is to place as much pressure as possibly possible on Jens Eriksson prior to next quarterly announcement as of 21th August. Do fell free to join in and contact Jens Eriksson - the more who raise their voices, the bigger the chance is he will disclose substantiated information to the market. He should know for sure his story-telling days are over........ <xxxx@xxxx.dk> 09/07/202510:47 To: xxxx@xxxx.dk, je@coeginpharma.com Cc: info@coeginpharma.com, erlend@sarsia.com Dear Jens, First, credit is due to you for now using the appropriate channels of the Swedish stock exchange to inform the market of developments at Coegin Pharma AB. Transparency is a vital step forward, and I thank you for taking that responsibility seriously. That said, the market's perception of Coegin Pharma AB remains negative. Despite recent announcements—such as the 80% reduction in production costs for the hair growth product and the presentation of its packaging prototype—the market has not responded positively. The share price continues its downward trend, signaling a lack of confidence that these updates signify meaningful progress toward commercialization and, ultimately, positive cash flow. Why is this the case? The answer appears to be straightforward: the market has grown weary of what it perceives as prolonged storytelling rather than evidence-backed execution. Cost savings and packaging design are not, in themselves, proof of market readiness or commercial viability. They do not address the key concerns investors have about Coegin Pharma AB's ability to evolve into a profitable startup. As CEO, it is now essential to provide the market with concrete, evidence-based information that substantiates the company’s go-to-market capability. Specifically, stakeholders need to see: - Names of signed partners and distributors - The geographic reach and coverage of these distribution networks - A clear, detailed product launch timeline including specific milestones - Transparent communication regarding the company’s financial position and upcoming funding requirements These are basic and expected elements of investor communication at this stage of company development. With this in mind, I strongly encourage you to sharpen the focus and clarity of Coegin Pharma AB’s messaging ahead of the upcoming quarterly report, scheduled for publication on August 21st. This is an opportunity to shift the narrative through concrete disclosures that build trust and demonstrate that the company is entering a phase of measurable execution. Sincerely, Xxxx Xxxx
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
180
Myynti
Määrä
2 110
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 89 | AVA | NON | ||
| 324 | AVA | NON | ||
| 1 060 | AVA | NON | ||
| 962 | NON | NON | ||
| 2 000 | ENS | NON |
Ylin
6,44VWAP
Alin
6,02VaihtoMäärä
0,4 69 421
VWAP
Ylin
6,44Alin
6,02VaihtoMäärä
0,4 69 421
Välittäjätilasto
Dataa ei löytynyt